FDA Application for Orphan Drug Designation , PAA, MPL, page-336

It's not bad news for monepantel because monepantel does what rapamycin does but with less adverse effects: Monepantel represents the first of the next gen mTOR inhibitors and increasingly like rapamycin's/sirolimus's successor for a whole range of therapies - and that's no small thing !!!

However, agree with your point about the importance of marketing and the implication of getting good public info out there more generally. NZ Trader especially has been banging the drum on this for a long time. Things are already changing on this front with MT in a number of ways.

Cheers